Skip to Main Content

Paper Details

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.
Mol Endocrinol
65
2015
AR, AR binding sites, Androgen, Androgen Receptor Cistrome, DUCaP cells, LAMC1, MCL1, Mcl-1, PCa, PCa cells, Prostate Cancer, advanced prostate cancer, androgen, androgen receptor, cancerous, downstream target genes, genomic AR binding sites, host genes, laminin gamma 1, miR, miR-, miR-17-92 cluster, miR-22, miR-29a, miRNAs, microRNAs, myeloid cell leukemia 1, primary, tumor, wild-type AR
Author NameAffiliation
Narisu NarisuMedical University of Innsbruck, Austria Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, National Human Genome Research Institute, National Institutes of Health, Austria Center for Biomedicine (J.R., Center for Personalized Cancer Medicine, Austria Max Planck Institute for Molecular Genetics (S.T.B., Germany Cologne Center for Genomics (M.R.S.), University of Cologne, University of Michigan ann arbor
Michal R SchweigerMedical University of Innsbruck, Austria Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, National Human Genome Research Institute, National Institutes of Health, Austria Center for Biomedicine (J.R., Center for Personalized Cancer Medicine, Austria Max Planck Institute for Molecular Genetics (S.T.B., Germany Cologne Center for Genomics (M.R.S.), University of Cologne, University of Michigan ann arbor
Christian FuchsbergerMedical University of Innsbruck, Austria Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, National Human Genome Research Institute, National Institutes of Health, Austria Center for Biomedicine (J.R., Center for Personalized Cancer Medicine, Austria Max Planck Institute for Molecular Genetics (S.T.B., Germany Cologne Center for Genomics (M.R.S.), University of Cologne, University of Michigan ann arbor
  • 1 - 3

Datasets

Release 1.2